BNGO - CIK 0001411690
The table below shows Bionano Genomics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$5.72M | -$2.76M | -$28.13M | -$32.41M | -$32.49M | -$13.90M |
| Capital expenditure | - | - | - | - | - | $24.00K |
| Investing cash flow | $5.46M | -$14.07M | $47.59M | $16.53M | $31.96M | -$24.00K |
| Dividends paid | - | - | - | - | - |
Bionano Genomics, Inc. reported operating cash flow of -$16.34M for fiscal year 2025. That is up 76.3% from -$68.92M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow grew from -$20.82M (FY 2017) to -$16.34M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $657.00K | $10.89M | -$21.62M | $14.86M | $7.00K | $337.54M |